Caris Life Sciences vs Tempus
The two listed precision oncology companies most cancer programmes end up comparing, and they are indexed here for different halves of what they sell. Caris is graded on the profiling itself, with an approved assay running simultaneous whole exome and whole transcriptome sequencing, published clinical and analytical validation, and signatures that disclose their training cohorts. Tempus is graded on the provider software: decision support that flags patients drifting off guideline care, physician tooling, and the most complete health privacy disclosure in this category, earned by documenting both its laboratory role and its software role. If the decision is which molecular profile to order, that is a Caris question. If it is which platform sits in the oncologist's workflow between tests, that is a Tempus question. Both should be read knowing the same company runs the laboratory and reports the performance.
- The regulatory distinction is documented rather than blurred: an approved assay performing simultaneous whole exome and whole transcriptome sequencing sits on a different footing from laboratory developed testing, and the company separates the two.
- Clinical and analytical validation of the approved assay is published, and the artificial intelligence signatures disclose their training cohorts and sizes rather than being described as proprietary.
- Scope is bounded precisely to solid tumour molecular profiling across adult and paediatric patients, which is a clearer statement of intended use than most of this category offers.
- The health privacy disclosure is the most complete in this category, and it is complete because the company occupies both sides of the relationship, laboratory and software vendor, and documents each.
- The provider software is the indexed product rather than the laboratory, so a health system is buying decision support and physician tooling rather than only a test result.
- Its stewardship disclosure is unusually full, publishing what it does with data rather than asserting compliance and stopping there.
Side by Side
| Axis | C Caris Life Sciences |
T Tempus |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Diagnostics & Genomics page.
Both companies operate their own clinical laboratories and sell software built on the data those laboratories generate, which is the structural fact to hold while reading any of their evidence: the same organisation orders the analysis, produces the result and reports the performance.
Neither publishes a security attestation or a trust centre, and neither publishes a bias evaluation or subgroup performance analysis, which matters in precision oncology because variant interpretation and signature performance both depend on the ancestral composition of the training cohorts. Neither publishes pricing for the software components, and the test side is reimbursed rather than listed.